Complete Story


U.S. FDA Vaccine Advisors Debate Boosters as Biden Administration Plans Rollout

Many question if the data suggest there is enough evidence for boosters

Debate over whether Americans should receive a booster dose of the Pfizer/BioNTech COVID-19 vaccine as planned by the Biden administration moved to a panel of independent expert advisers to the U.S. Food and Drug Administration (FDA) on Friday.

While U.S. health officials, some other countries and vaccine makers have said boosters are needed, many scientists, including some inside the FDA and the U.S. Centers for Disease Control and Prevention (CDC), disagree.

Many of them have said that while there is growing evidence that boosters provide increased protection against severe disease to people aged 65 and older, there is not enough evidence that they are needed broadly.

Please select this link to read the complete article from Reuters.

Printer-Friendly Version